Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study
J Eur Acad Dermatol Venereol, 2020.
Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM; BADBIR Study Group.
Read publication: J Eur Acad Dermatol Venereol
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for pa...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
0 Comments